Bellerophon Therapeutics has completed participants enrolment in the Phase III REBUILD study of its pulsatile nitric oxide delivery system, INOpulse, to treat fibrotic interstitial lung disease (fILD).

The double-blind, randomised, placebo-controlled, dose escalation and verification Phase III clinical trial has been designed for assessing the efficacy and safety of pulsed inhaled nitric oxide (iNO) in patients who are at risk for pulmonary hypertension that is associated with pulmonary fibrosis on long-term oxygen therapy.

A total of 145 participants have been enrolled in the trial.

The change in moderate to vigorous physical activity (MVPA) as measured by an actigraphy is the study’s primary endpoint.

Nitric oxide is a molecule which is naturally produced in the endothelial lining of blood vessels. It plays an important role in vasodilation, or the opening of the arteries, such as the arteries in the lung.

The company anticipates to receive the pivotal top-line results from the trial in the middle of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bellerophon Therapeutics CEO Peter Fernandes said: “This study will provide the randomised dataset to evaluate the change in moderate to vigorous physical activity (MVPA) following treatment with INOpulse in patients with fILD.

“These patients struggle to perform basic activities of daily living such as walking, climbing stairs, or showering.

“The ability to monitor changes in their level of physical activity, specifically the difference in MVPA as the novel endpoint, which correlates to household tasks and activities of daily living, has the potential to inform directly on the patient’s overall health, well-being, and quality of life.”

It intends to use the data from the REBUILD study for the submission of the new drug application (NDA) for approval of INOpulse to treat fILD.